Graham Peter Lidgard Sells 37,613 Shares of EXACT Sciences Co. (EXAS) Stock

EXACT Sciences Co. (NASDAQ:EXAS) insider Graham Peter Lidgard sold 37,613 shares of the company’s stock in a transaction on Monday, November 5th. The stock was sold at an average price of $75.01, for a total transaction of $2,821,351.13. Following the transaction, the insider now directly owns 29,398 shares in the company, valued at $2,205,143.98. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Graham Peter Lidgard also recently made the following trade(s):

  • On Wednesday, November 7th, Graham Peter Lidgard sold 38,311 shares of EXACT Sciences stock. The stock was sold at an average price of $75.01, for a total transaction of $2,873,708.11.
  • On Thursday, November 1st, Graham Peter Lidgard sold 79,673 shares of EXACT Sciences stock. The stock was sold at an average price of $71.73, for a total transaction of $5,714,944.29.
  • On Monday, October 8th, Graham Peter Lidgard sold 58,000 shares of EXACT Sciences stock. The stock was sold at an average price of $69.36, for a total transaction of $4,022,880.00.

NASDAQ:EXAS opened at $76.08 on Friday. The stock has a market capitalization of $9.12 billion, a price-to-earnings ratio of -76.85 and a beta of 1.21. The company has a debt-to-equity ratio of 0.94, a quick ratio of 11.72 and a current ratio of 12.08. EXACT Sciences Co. has a 12-month low of $37.36 and a 12-month high of $81.22.

EXACT Sciences (NASDAQ:EXAS) last released its earnings results on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.05. The company had revenue of $118.29 million for the quarter, compared to analyst estimates of $109.33 million. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.18%. The firm’s quarterly revenue was up 63.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.23) EPS. Analysts forecast that EXACT Sciences Co. will post -1.53 earnings per share for the current year.

Several research firms recently commented on EXAS. Benchmark reiterated a “hold” rating on shares of EXACT Sciences in a research report on Wednesday, September 5th. Cowen boosted their price objective on shares of EXACT Sciences from $65.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 5th. Craig Hallum boosted their price objective on shares of EXACT Sciences from $54.00 to $74.00 and gave the stock a “buy” rating in a research report on Thursday, August 23rd. BidaskClub lowered shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. Finally, Zacks Investment Research upgraded shares of EXACT Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, August 21st. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $84.08.

A number of large investors have recently added to or reduced their stakes in the business. Xact Kapitalforvaltning AB lifted its holdings in EXACT Sciences by 4.5% in the 3rd quarter. Xact Kapitalforvaltning AB now owns 18,725 shares of the medical research company’s stock valued at $1,478,000 after purchasing an additional 800 shares in the last quarter. Chicago Partners Investment Group LLC lifted its holdings in EXACT Sciences by 47.6% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 3,100 shares of the medical research company’s stock valued at $191,000 after purchasing an additional 1,000 shares in the last quarter. MML Investors Services LLC lifted its holdings in EXACT Sciences by 38.0% in the 3rd quarter. MML Investors Services LLC now owns 5,050 shares of the medical research company’s stock valued at $399,000 after purchasing an additional 1,391 shares in the last quarter. Swiss National Bank lifted its holdings in EXACT Sciences by 0.9% in the 3rd quarter. Swiss National Bank now owns 212,619 shares of the medical research company’s stock valued at $16,780,000 after purchasing an additional 2,000 shares in the last quarter. Finally, IFP Advisors Inc lifted its holdings in EXACT Sciences by 49.4% in the 3rd quarter. IFP Advisors Inc now owns 6,192 shares of the medical research company’s stock valued at $489,000 after purchasing an additional 2,047 shares in the last quarter. Institutional investors own 87.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Graham Peter Lidgard Sells 37,613 Shares of EXACT Sciences Co. (EXAS) Stock” was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2018/11/09/graham-peter-lidgard-sells-37613-shares-of-exact-sciences-co-exas-stock.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: How to use beta for portfolio diversification

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply